HIGHLIGHTS
- who: Zhiqing Bai from the Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China have published the research: Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1u2013 Mediated Gemcitabine Chemoresistance, in the Journal: (JOURNAL)
- what: This study was approved by the Ethics Committee of the Beijing Tsinghua Changgung Hospital, and informed consent was obtained prior to surgery. The study demonstrates that HER2-overexpressed CCA is sensitive to lapatinib treatment in_vitro. The study provides clear evidence that lapatinib can be substantially coordinated with gemcitabine as a first line treatment for HER2-overexpressed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.